Seattle Genetics Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Seattle Genetics (SGEN) PT Lowered to $92 at RBC Capital
October 26, 2018 7:35 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $92.00 (from $98.00) while maintaining a Outperform rating.
The analyst notes the surprise Adcetris miss brings questions to 1L HL aspect of bull thesis.
... MoreSeattle Genetics (SGEN) Sinks Following Q3 Results, Q4 Outlook
October 25, 2018 5:40 PM EDTSeattle Genetics (NASDAQ: SGEN) is down 16% after-hours after the company reported Q3 EPS of ($0.34), $0.07 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $169.4 million versus the consensus estimate of $166.92 million.
The company sees Q4 ADCETRIS net product sales of $128-$133 million and FY 2018 ADCETRIS net product sales of $473-$478 million.
ADCETRIS... More
